Capmatinib price summary

Capmatinib (Capmatinib, also known as Tabrecta), a targeted drug for non-small cell lung cancer produced by Novartis Pharmaceuticals, has attracted much attention in recent years. However, many patients are often confused by the price difference when searching for this drug. Today, we will reveal the various versions of capmatinib and their prices.

First, let’s focus on the original drug. The European original research version of capmatinib is priced at about 57,000 per box (200mg*120 tablets). The Hong Kong original research version has different specifications. Each box is 200mg*60 tablets, and the price is about 35,000. It is worth noting that there are no differences in original drugs across the world, and price differences are mainly affected by exchange rates and local medical policies. When purchasing, patients must ensure that the medicine is genuine and use it under the guidance of a doctor.

Next, let’s look at generic drugs. The price of generic drugs is generally lower than that of original drugs, providing treatment possibilities for more patients. For example, the Laos Lucius version of capmatinib (200mg*60 tablets) sells for about 3,500 yuan per box. The price of the Laos Big Bear version (200mg*56 tablets) is only more than 3,000. These generic drugs have been approved by the Lao government and are officially marketed drugs, and patients can use them with confidence.

In addition, there are also versions jointly produced by Laos and versions with Laos elements on the market, and their prices range from 3,000 to more than 4,000 yuan. These versions are produced by regular pharmaceutical factories, and their quality is guaranteed to a certain extent.

When choosing, patients should make their decision based on their financial situation and the advice of their doctor. At the same time, we must be wary of counterfeit and inferior drugs on the market to ensure the safety of medication.